Europeiska unionen - estniska - EMA (European Medicines Agency)

sandoz gmbh - natalisumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosupressandid - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 ja 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Europeiska unionen - estniska - EMA (European Medicines Agency)

tillotts pharma gmbh - fidaksomitsiin - clostridium infektsioonid - antidiarrheals, soole põletikuvastased / antiinfective ained - dificlir õhukese polümeerikattega tabletid on näidustatud ravi clostridioides difficile infektsioonide (cdi), tuntud ka kui c. raske-seotud diarröa (cdad), täiskasvanud ja pediaatriliste patsientide puhul, kelle kehakaal on vähemalt 12. 5 kg. tähelepanu tuleks pöörata euroopa liidu suuniste kohta asjakohast kasutamist antibakteriaalseid aineid. dificlir graanulite suukaudne suspensioon on näidustatud ravi clostridioides difficile infektsioonide (cdi), tuntud ka kui c. raske-seotud diarröa (cdad) täiskasvanud ja pediaatriliste patsientide sünnist kuni < 18-aastane. tähelepanu tuleks pöörata euroopa liidu suuniste kohta asjakohast kasutamist antibakteriaalseid aineid.

Europeiska unionen - estniska - EMA (European Medicines Agency)

itm medical isotopes gmbh - lutetium (177lu) chloride - radionukliidi pildistamine - terapeutilised radiofarmatseutilised ühendid - endolutsiinbeta on radiofarmatseutiline prekursor ja see ei ole ette nähtud patsientide otseseks kasutamiseks. seda tuleb kasutada ainult spetsiaalselt välja töötatud ja lutetiumi (177lu) kloriidi radioaktiivse märgistamise jaoks kinnitatud kandemolekulide radiomärgistamiseks.

Europeiska unionen - estniska - EMA (European Medicines Agency)

corza medical gmbh - inimese fibrinogeen, inimese trombiin - hemostaas, kirurgiline - antihemorraagilised ained - tachosil is indicated in adults and children from 1 month of age for supportive treatment in surgery for improvement of haemostasis, to promote tissue sealing and for suture support in vascular surgery where standard techniques are insufficient. tachosil is indicated in adults for supportive sealing of the dura mater to prevent postoperative cerebrospinal leakage following neurological surgery (see section 5.

Europeiska unionen - estniska - EMA (European Medicines Agency)

eisai gmbh - alitretinoiin - sarkoom, kaposi - antineoplastilised ained - panretin geel on näidustatud paikseks raviks naha kahjustus patsientidel, kellel on omandatud-immuunsüsteemi puudulikkus-sündroom (aids) seotud kaposi on sarkoom (ks), kui:kahjustused ei ole ulcerated või lymphoedematous, ja;ravi vistseraalse ks ei pea, ja;kahjustused, mis ei vasta süsteemseid retroviirusevastast ravi, ja;kiiritusravi või kemoteraapia ei ole asjakohane.

Europeiska unionen - estniska - EMA (European Medicines Agency)

era consulting gmbh - pegfilgrastim - neutropeenia - immunostimulants, , mesilaspere stimuleerivaid faktoreid - neutropeenia ja febriilse neutropeenia esinemissageduse vähendamine ravitud tsütotoksilise kemoteraapia pahaloomulise kasvaja (välja arvatud krooniline müeloidne leukeemia ja müelodüsplastilised sündroomid).

Europeiska unionen - estniska - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaktsiinid - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.

Europeiska unionen - estniska - EMA (European Medicines Agency)

pinax pharma gmbh - ioflupane (123i) - radionuclide imaging; dementia; movement disorders - diagnostilised radiofarmatseutilised ühendid - see ravim on mõeldud ainult diagnostiliseks kasutamiseks. celsunax is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:in adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic parkinson’s disease, multiple system atrophy and progressive supranuclear palsy.  celsunax is unable to discriminate between parkinson's disease, multiple system atrophy and progressive supranuclear palsy. täiskasvanud patsientidel, et aidata eristada arvatav dementsus koos lewy kehad alzheimeri tõbi.  celsunax is unable to discriminate between dementia with lewy bodies and parkinson’s disease dementia.

Estland - estniska - Ravimiamet

ideal trade links uab - aselaiinhape - kreem - 200mg 1g 30g 1tk

Estland - estniska - Ravimiamet

ideal trade links uab - metotreksaat - tablett - 2,5mg 100tk